Your browser doesn't support javascript.
loading
Tailoring of an anti-diabetic drug empagliflozin onto zinc oxide nanoparticles: characterization and in vitro evaluation of anti-hyperglycemic potential.
Shoaib, Abdullah; Shahid, Sammia; Mansoor, Sana; Javed, Mohsin; Iqbal, Shahid; Mahmood, Sajid; Bahadur, Ali; Jaber, Fadi; Alshalwi, Matar.
Affiliation
  • Shoaib A; Department of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
  • Shahid S; Department of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
  • Mansoor S; Department of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
  • Javed M; Department of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
  • Iqbal S; Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, 315100, China. Shahid.Iqbal@nottingham.edu.cn.
  • Mahmood S; Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, 315100, China.
  • Bahadur A; Functional Materials Group, Gulf University for Science and Technology, 32093, Mishref, Kuwait.
  • Jaber F; Department of Chemistry, College of Science, Mathematics, and Technology, Wenzhou-Kean University, Wenzhou, 325060, China. abahadur@wku.edu.cn.
  • Alshalwi M; Dorothy and George Hennings College of Science, Mathematics and Technology, Kean University, 1000 Morris Ave, Union, New Jersey, 07083, USA. abahadur@wku.edu.cn.
Sci Rep ; 14(1): 2499, 2024 01 30.
Article in En | MEDLINE | ID: mdl-38291095
ABSTRACT
Diabetes is a serious health issue that can be a great risk factor related to numerous physical problems. A class of drugs "Gliflozin" especially Sodium Glucose Co. Transporter 2 was inhibited by a novel drug, which is known as "empagliflozin". While ZnO nanoparticles (NPs) had considerable promise for combating diabetes, it was employed in the treatment and management of type-2 diabetes mellitus. The new drug empagliflozin was initially incorporated into Zinc Oxide NPs in this study using the surface physio-sorption technique, and the degree of drug adsorption was assessed using the HPLC method. The tailored product was characterized by using the FTIR, EDX, Ultraviolet-Visible, XRD and SEM techniques. With an average particle size of 17 nm, SEM revealed mono-dispersion of NPs and sphere-like form. The Freundlich isotherm model best fits and explains the data for the physio-sorption investigation, which examined adsorption capabilities using adsorption isotherms. The enzymes α-amylase and α-glucosidase, which are involved in the human metabolism of carbohydrates, were used in the in-vitro anti-diabetic assays. It was discovered that the composite showed the highest levels of 81.72 and 92.77% inhibition of -α-amylase and -glucosidase at an absolute concentration of 1000 µg per ml with IC50 values of 30.6 µg per ml and 72 µg per ml.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Zinc Oxide / Benzhydryl Compounds / Diabetes Mellitus, Type 2 / Nanoparticles / Metal Nanoparticles / Glucosides Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country: Pakistan Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Zinc Oxide / Benzhydryl Compounds / Diabetes Mellitus, Type 2 / Nanoparticles / Metal Nanoparticles / Glucosides Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Sci Rep Year: 2024 Document type: Article Affiliation country: Pakistan Country of publication: United kingdom